title: Pefloxacin versus chloramphenicol in the therapy of typhoid fever.
abstract: An open, randomized clinical study was carried out to compare the clinical efficacy and safety of pefloxacin with that of chloramphenicol in the treatment of typhoid fever. Sixty hospitalized patients (40 men and 20 women, aged from 17 to 64 years), affected by severe proven typhoid sepsis, were randomly assigned to treatment with pefloxacin at a daily dose of 1,200 mg for 15 days (Group A) or with chloramphenicol at a daily dose of 2 g for 15 days (Group B). The two groups of patients were statistically homogeneous regarding both age and sex and all patients were followed for 30 days after the end of therapy. In Group A all the patients completely recovered from infection and all the isolated strains of Salmonella typhi were eradicated by pefloxacin treatment. In Group B two patients had a relapse, two patients became chronic enteric carriers of S. typhi and only 26 patients recovered from infection with complete eradication of the pathogen. The results indicate that pefloxacin is as active as chloramphenicol in the therapy of typhoid fever and that pefloxacin could be a valid antibacterial agent to be used together with appropriate hygienic measures for an eradication program of typhoid fever in the endemic countries.
authors.affiliation: Dipartimento di Internistica Clinica e Sperimentale F. Magrassi, IV Clinica Medica Generale, Nuovo Policlinico di Napoli, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Cristiano
authors.forename: L
authors.initials: L
authors.lastname: Imparato
authors.forename: C
authors.initials: C
authors.lastname: Carpinelli
authors.forename: F
authors.initials: F
authors.lastname: Lauria
authors.forename: M R
authors.initials: MR
authors.lastname: Iovene
authors.forename: M F
authors.initials: MF
authors.lastname: Corrado
authors.forename: P
authors.initials: P
authors.lastname: Maio
authors.forename: C
authors.initials: C
authors.lastname: Imperatore
mesh_terms: D000293:Adolescent; D000328:Adult; D002701:Chloramphenicol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015366:Pefloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D014435:Typhoid Fever / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D015366:Pefloxacin; D002701:Chloramphenicol